The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers

Virus Research

Volumn 121, Issue 2, 2006, Pages 220-222

  Marais, Dianne ^a   Carrara, Henri ^a   Kay, Patti ^a   Ramjee, Gita ^b   Allan, Bruce ^a   Williamson, Anna Lise ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Medical   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Human papillomavirus; Nonoxynol 9; Vaginal microbicides

Indexed keywords

NONOXINOL 9;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RISK; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSTITUTION; VIRUS INFECTION; WART VIRUS;

ADMINISTRATION, INTRAVAGINAL; CERVIX UTERI; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DNA, VIRAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; NONOXYNOL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSTITUTION; SOUTH AFRICA; SPERMATOCIDAL AGENTS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VAGINAL CREAMS, FOAMS, AND JELLIES;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS;

EID: 33748936111     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2006.04.009     Document Type: Article

References (11)

1. Broker T.R., Jin G., Croom-Rivers A., Bragg S.M., Richardson M., Chow L.T., Vermund S.H., Alvarez R.D., Pappas P.G., Squires K.E., and Hoesley C.J. Viral latency-the papillomavirus model. Dev. Biol. (Basel) 106 (2001) 443-451
2. Celentano D.D. Oral contraceptives and cervical cancer. JAMA 259 (1988) 2696-2697
3. Dalgleish A.G., and O'Byrne K.J. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv. Cancer Res. 84 (2002) 231-276
4. Dayal M.B., Wheeler J., Williams C.J., and Barnhart K.T. Disruption of the upper female reproductive tract epithelium by nonoxynol-9. Contraception 68 (2003) 273-279
5. Fichorova Riana N., Tucker Lynne D., and Anderson Debora J. The molecular basis of Nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodefiency virus type 1 transmission. J. Infect. Dis. 184 (2001) 418-428
6. Gravitt P.E., Peyton C.L., Alessi T.Q., Wheeler C.M., Coutlee F., Hildesheim A., Schiffman M.H., Scott D.R., and Apple R.J. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38 (2000) 357-361
7. Howett M.K., and Kuhl J.P. Microbicides for prevention of transmission of sexually transmitted diseases. Curr. Pharm. Des. 11 (2005) 3731-3746
8. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
9. Kreiss J., Ngugi E., Holmes K., Ndinya-achola J., Waiyaki P., Roberts P.L., Ruminjo I., Sajabi R., Kimata J., and Fleming T.R. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268 (1992) 477-482
10. Sitas, F., Blaauw, D., Terblanche, M., Madhoo, J., Carrara, H., 1998. Incidence of histological diagnosed cancer in South Africa, 1992. National Cancer Registry of South Africa, South African Institute for Medical Research, Johannesburg. Ref Type: Report.
11. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Mukenge-Tshibaka L., Ettiegne-Traore V., Uaheowitchai C., Karim S.S., Masse B., Perriens J., and Laga M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002) 971-977